يعرض 1 - 20 نتائج من 260 نتيجة بحث عن '"N V Petrova"', وقت الاستعلام: 0.75s تنقيح النتائج
  1. 1
    Academic Journal
  2. 2
    Academic Journal
  3. 3
    Academic Journal

    المصدر: Research and Practical Medicine Journal; Том 10, № 3 (2023); 69-79 ; Research'n Practical Medicine Journal; Том 10, № 3 (2023); 69-79 ; 2410-1893 ; 10.17709/10.17709/2410-1893-2023-10-3

    وصف الملف: application/pdf

    Relation: https://www.rpmj.ru/rpmj/article/view/901/584; Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021 May;71(3):209–249. https://doi.org/10.3322/caac.21660; Tan W, Yang M, Yang H, Zhou F, Shen W. Predicting the response to neoadjuvant therapy for early-stage breast cancer: Tumor-, blood-, and imaging-related biomarkers. Cancer Manag Res. 2018 Oct 9;10:4333–4347. https://doi.org/10.2147/cmar.s174435; Puglisi F, Follador A, Minisini AM, Cardellino GG, Russo S, Andreetta C, Di Terlizzi S, Piga A. Baseline staging tests aſter a new diagnosis of breast cancer: further evidence of their limited indications. Ann Oncol. 2005 Feb;16(2):263–266. https://doi.org/10.1093/annonc/mdi063; Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN, Pusztai L. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008 Mar 10;26(8):1275–1281. https://doi.org/10.1200/jco.2007.14.4147. Epub 2008 Feb 4. Corrected and republished in: J Clin Oncol. 2023 Apr 1;41(10):1809-1815.; Funt SA, Chapman PB. The Role of Neoadjuvant Trials in Drug Development for Solid Tumors. Clin Cancer Res. 2016 May 15;22(10):2323–2328. https://doi.org/10.1158/1078-0432.ccr-15-1961; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol. 2018 Jan;19(1):27–39. https://doi.org/10.1016/s1470-2045(17)30777-5; Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: The CTNeoBC pooled analysis. Lancet. 2014 Jul 12;384(9938):164-172. https://doi.org/10.1016/s0140-6736(13)62422-8. Erratum in: Lancet. 2019 Mar 9;393(10175):986.; Gradishar WJ, Moran MS, Abraham J, Aſt R, Agnese D, Allison KH, et al. Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023 Mar.;23 (Version 4.2023). Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf; Korde LA, Somerfield MR, Carey LA, Crews JR, Denduluri N, Hwang ES, et al. Neoadjuvant chemotherapy, endocrine therapy, and targeted therapy for breast cancer: ASCO Guideline. J Clin Oncol. 2021 May 1;39(13):1485–1505. https://doi.org/10.1200/jco.20.03399; Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: A randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013 Sep;24(9):2278–2284. https://doi.org/10.1093/annonc/mdt182; Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, et al. Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015 Jan 1;33(1):13–21. https://doi.org/10.1200/jco.2014.57.0572; Garutti M, Griguolo G, Botticelli A, Buzzatti G, De Angelis C, Gerratana L, et al. Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review. Cancers (Basel). 2022 Apr 9;14(8):1898. https://doi.org/10.3390/cancers14081898; Kong X, Moran MS, Zhang N, Haffty B, Yang Q. Meta-Analysis Confirms Achieving Pathological Complete Response Aſter Neoadjuvant Chemotherapy Predicts Favourable Prognosis for Breast Cancer Patients. Eur J Cancer. 2011;47(14):2084–2090. https://doi.org/10.1016/j.ejca.2011.06.014; Scheel JR, Kim E, Partridge SC, Lehman CD, Rosen MA, Bernreuter WK, et al. MRI, Clinical Examination, and Mammography for Preoperative Assessment of Residual Disease and Pathologic Complete Response Aſter Neoadjuvant Chemotherapy for Breast Cancer: ACRIN 6657 Trial. AJR Am J Roentgenol. 2018;210(6):1376–1385. https://doi.org/10.2214/ajr.17.18323; Gampenrieder SP, Peer A, Weismann C, Meissnitzer M, Rinnerthaler G, Webhofer J, et al. Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) aſter neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR). Breast Cancer Res. 2019 Jan 31;21(1):19. https://doi.org/10.1186/s13058-018-1091-y; O’Donnell JPM, Gasior SA, Davey MG, O’Malley E, Lowery AJ, McGarry J, et al. The accuracy of breast MRI radiomic methodologies in predicting pathological complete response to neoadjuvant chemotherapy: A systematic review and network meta-analysis. Eur J Radiol. 2022 Dec;157:110561. https://doi.org/10.1016/j.ejrad.2022.110561; Hong J, Rui W, Fei X, Chen X, Shen K. Association of tumor-infiltrating lymphocytes before and aſter neoadjuvant chemotherapy with pathological complete response and prognosis in patients with breast cancer. Cancer Med. 2021 Nov;10(22):7921–7933. https://doi.org/10.1002/cam4.4302; Teng MW, Ngiow SF, Ribas A, Smyth MJ. Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Res. 2015 Jun 1;75(11):2139–2145. https://doi.org/10.1158/0008-5472.can-15-0255; Yamaguchi R, Tanaka M, Yano A, Tse GM, Yamaguchi M, Koura K, et al. Tumor-infiltrating lymphocytes are important pathologic predictors for neoadjuvant chemotherapy in patients with breast cancer. Hum Pathol. 2012 Oct;43(10):1688–1694. https://doi.org/10.1016/j.humpath.2011.12.013; Verma C, Kaewkangsadan V, Eremin JM, Cowley GP, Ilyas M, El-Sheemy MA, Eremin O. Natural killer (NK) cell profiles in blood and tumour in women with large and locally advanced breast cancer (LLABC) and their contribution to a pathological complete response (PCR) in the tumour following neoadjuvant chemotherapy (NAC): differential restoration of blood profiles by NAC and surgery. J Transl Med. 2015 Jun 4;13:180. https://doi.org/10.1186/s12967-015-0535-8; Malyguine AM, Strobl SL, Shurin MR. Immunological monitoring of the tumor immunoenvironment for clinical trials. Cancer Immunol Immunother. 2012 Feb;61(2):239–247. https://doi.org/10.1007/s00262-011-1148-6; Li C, Lu N, He Z, Tan Y, Liu Y, Chen Y, et al. A Noninvasive Tool Based on Magnetic Resonance Imaging Radiomics for the Preoperative Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. Ann Surg Oncol. 2022 Nov;29(12):7685–7693. https://doi.org/10.1245/s10434-022-12034-w; Gu YL, Pan SM, Ren J, Yang ZX, Jiang GQ. Role of Magnetic Resonance Imaging in Detection of Pathologic Complete Remission in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: A Meta-analysis. Clin Breast Cancer. 2017 Jul;17(4):245–255. https://doi.org/10.1016/j.clbc.2016.12.010; Cao K, Zhao B, Li XT, Li YL, Sun YS. Texture Analysis of Dynamic Contrast-Enhanced MRI in Evaluating Pathologic Complete Response (pCR) of Mass-Like Breast Cancer aſter Neoadjuvant Therapy. J Oncol. 2019 Dec 26;2019:4731532. https://doi.org/10.1155/2019/4731532; Shukla-Dave A, Obuchowski NA, Chenevert TL, Jambawalikar S, Schwartz LH, Malyarenko D, et al. Quantitative imaging biomarkers alliance (QIBA) recommendations for improved precision of DWI and DCE-MRI derived biomarkers in multicenter oncology trials. J Magn Reson Imaging. 2019 Jun;49(7):e101–e121. https://doi.org/10.1002/jmri.26518; https://www.rpmj.ru/rpmj/article/view/901

  4. 4
    Academic Journal

    المساهمون: This publication is supported by ALPHARMA LLC company., Статья опубликована при финансовой поддержке Общества с ограниченной ответственностью «АЛФАРМА».

    المصدر: PULMONOLOGIYA; Том 33, № 4 (2023); 510-516 ; Пульмонология; Том 33, № 4 (2023); 510-516 ; 2541-9617 ; 0869-0189

    وصف الملف: application/pdf

    Relation: https://journal.pulmonology.ru/pulm/article/view/4307/3555; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4307/2061; https://journal.pulmonology.ru/pulm/article/downloadSuppFile/4307/2062; Worlitzsch D., Tarran R., Ulrich M. et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J. Clin. Invest. 2002; 109 (3): 317–325. DOI:10.1172/JCI0213870.; Кондратьева Е.И., Красовская С.А., Старинова М.А. и др., ред. Регистр пациентов с муковисцидозом в Российской Федерации. 2020 год. М.: Медпрактика-М; 2022. Доступно на: https://api.med-gen.ru/site/assets/files/51107/site_registre_2020.pdf; Rutter W.C., Burgess D.R., Burgess D.S. Increasing incidence of multidrug resistance among cystic fibrosis respiratory bacterial isolates. Microb. Drug Resist. 2017; 23 (1): 51–55. DOI:10.1089/mdr.2016.0048.; Cystic Fibrosis Foundation. Patient Registry 2021 Annual Data Report. Bethesda, Maryland; 2022. Available at: https://www.cff.org/sites/default/files/2021-11/Patient-Registry-Annual-Data-Report.pdf; Döring G., Flume P., Heijerman H. et al. Consensus study G. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J. Cyst. Fibros. 2012; 11 (6): 461–479. DOI:10.1016/j.jcf.2012.10.004.; Ryan C., Ross S., Davey P. et al. Prevalence and causes of prescribing errors: the PRescribing outcomes for trainee doctors engaged in clinical training (PROTECT) study. PLoS One. 2014; 9 (1): e79802. DOI:10.1371/journal.pone.0079802.; Mogayzel P.J., Naurckas E.T., Robinson K.A. et al. Cystic fibrosis foundation pulmonary guideline: pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection. Ann. Am. Thorac. Soc. 2010; 11 (10): 1640–1650. DOI:10.1513/AnnalsATS.201404-166OC.; Koerner-Rettberg C., Ballmann M. Colistimethate sodium for the treatment of chronic pulmonary infection in cystic fibrosis: an evidence-based review of its place in therapy. Core Evid. 2014; 9: 99–112. DOI:10.2147/CE.S64980.; Evans M.E., Feola D.J., Rapp R.P. Polymyxin B sulfate and colistin: old antibiotics for emerging multiresistant gram-negative bacteria. Ann. Pharmacother. 1999; 33 (9): 960–967. DOI:10.1345/aph.18426.; Rogers M.J., Cohen J. Comparison of the binding of gram-negative bacterial endotoxin by polymyxin B sulphate, colistin sulphate and colistin sulphomethate sodium. Infection. 1986; 14 (2): 79–81. DOI:10.1007/BF01644448.; Gaibani P., Lombardo D., Lewis R.E. et al. In vitro activity and postantibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolates. J. Antimicrob. Chemother. 2014; 69 (7): 1856–1865. DOI:10.1093/jac/dku065.; Biswas S., Brunel J.M., Dubus .J.C. et al. Colistin: an update on the antibiotic of the 21st century. Expert Rev. Anti Infect. Ther. 2012; 10 (8): 917–934. DOI:10.1586/eri.12.78.; Taccetti G., Francalanci M., Pizzamiglio G. et al. Cystic fibrosis: recent insights into inhaled antibiotic treatment and future perspectives. Antibiotics (Basel). 2021; 10 (3): 338. DOI:10.3390/antibiotics10030338.; Alkhoury R., Kinkar E., Nokhbeh R., Saleh M.T. Monotherapy versus combination therapy for the treatment of Pseudomonas aeruginosa in cystic fibrosis patients. J. Antibiot. Res. 2018; 2 (1): 105. DOI:10.15744/2574-5980.2.105.; Ratjen F., Moeller A., McKinney M.L. et al. Eradication of early P. aeruginosa infection in children < 7years of age with cystic fibrosis: the early study. J. Cyst. Fibros. 2019; 18 (1): 78–85. DOI:10.1016/j.jcf.2018.04.002.; Министерство здравоохранения Российской Федерации. Кистозный фиброз (муковисцидоз): клинические рекомендации. 2021. Доступно на: https://cr.minzdrav.gov.ru/schema/372_2; Министерство здравоохранения Российской Федерации. Приказ № 835н «Об утверждении стандарта медицинской помощи детям при кистозном фиброзе (муковисцидозе) (диагностика, лечение и диспансерное наблюдение)». 2021. Доступно на: https://docs.cntd.ru/document/608494977; https://journal.pulmonology.ru/pulm/article/view/4307

  5. 5
    Academic Journal
  6. 6
    Academic Journal
  7. 7
    Academic Journal
  8. 8
    Academic Journal

    المصدر: The Herald of the Siberian State University of Telecommunications and Information Science; № 1 (2013); 110-118 ; Вестник СибГУТИ; № 1 (2013); 110-118 ; 1998-6920

    وصف الملف: application/pdf

    Relation: https://vestnik.sibsutis.ru/jour/article/view/395/379; ГОСТ Р 54316-2011 Воды минеральные природные питьевые. Общие технические условия [Электронный ресурс]. – Режим доступа: protect.gost.ru. – Загл. с экрана.; Петрова Н.В. Водопользование в совершенствовании механизма рационального освоения природной среды территории // Сб. трудов научно-практич. конфер. «СУЭБ-2009». – Екатеринбург: УГТУ-УПИ, 2009. – С. 55-60.; Петрова Н.В. Гидроресурсы и здоровье населения Республики Алтай // Вода: химия и экология. 2010. № 9. С. 46–50.; ООН. Конвенции и соглашения. [Электронный ресурс]. URL: http://www.un.org/ru/documents/decl_conv/conventions (дата обращения: 12.08.2007).; Джабарова Н. К., Яковенко Э. С., Коханенко А.А. Курортно-рекреационный потенциал Прителецкой территории Турочакского района Республики Алтай // Современные проблемы геоэкологии горных территорий. 2007. С. 194-200.; Кац В.Е. Минеральные, минерализованные и экологически чистые воды на территории Республики Алтай и их использование // Минерально-сырьевая база Республики Алтай: состояние и перспективы развития. 1998. С. 70-72.; Ушакова В.Г. Об использовании природных вод Республики Алтай // Минерально-сырьевая база Республики Алтай: состояние и перспективы развития. Матер. рег. совещания. Горно-Алтайск, 1998. – С. 72-79.; Схема развития и размещения объектов туризма в Республике Алтай до 2020 года. 2005.; Вальд А. Последовательный анализ: Пер. с англ. – М.: Физматлит, 1960. – 328 с.; Шалмина Г.Г., Каймина К.В. Природный рекреационный потенциал – основа развития лечебно-профилактической маршрутной деятельности (методический подход к оценке): монография. Новосибирск: Новосиб. гос. ун-т, 2006. 147 с.; Шалмина Г.Г. Предпроектное обоснование прогнозирования экономики: монография. Новосибирск: Издательство НГОНБ, НГУ, 2011. 480 с.; https://vestnik.sibsutis.ru/jour/article/view/395

  9. 9
    Academic Journal

    المصدر: PULMONOLOGIYA; № 3 (1994); 33-36 ; Пульмонология; № 3 (1994); 33-36 ; 2541-9617 ; 0869-0189

    وصف الملف: application/pdf

    Relation: https://journal.pulmonology.ru/pulm/article/view/3606/2974; Баранов B.C., Горбунова В.H., Иващенко Т.Э. Пренатальная диагностика, медико-генетическое консультирование и профилактика муковисцидоза (кистозного фиброза): Метод, рекомендации.— М ., 1991.; Бочкова Д.H., Громов Р.В., Вренеева A.C., Куандыков Е.У., Поморская Л.А., Реутова И.В. / / Педиатрия.— 1974.— No 12.— С.24—26.; Baranov V.S., Ivaschenko Т.E., Gorbunova V.N., Osynovskaya N.S., GembovskayaS.A. / / Pediatr. Pulmonol.— 1991.— Suppl.6.— P.244.; Boat T.E., Welsh M.S., Beaudet A.L. / / The Metabolic Basis of Inherited Disease / Ed. C.R. Scriver, A.L. Beaudet, W.S. Siy, D. Valle. 6-th Ed.— New York, 1989,— P.2649—2680.; Collins F.S. / / Pediatr. Pulmonol.— 1992.— Suppl.8.— P.63—64.; Eiberg H., Schmiegelow K., Tsui L.-C., Buchwad M., Niebuhr E., Phelan P.D., Willamson R., Warwick W., Koch C., Mohr J. / / Cytogenet. Cell G enet.— 1985.— Vol.40.— P .623.; Kerem В.-S., Rommens J.M., Buchanan S.A., Markiewicz D., Сох Т.К., Chakravarti A., Buchwald М., Tsui L.-C. / / Science.— 1989.— Vol.245.— P.1073—1080.; Knowlton R.G., Cohen-Haguenauer О., Van Cong N., Frezal S., Brown V.A., Barker D., Braman S.C., Shumm S.W., Tsui L.-C., Buchwald M., Donnis-Keller H. / / Nature.— 1985.— Vol.318.— P.380—382.; Monaco A.P., Kunkel L.M. / / Trends Genet.— 1987.— Vol.3.— p 33-37; Rao D.C., Morton N.E. / / Am. J. Hum. Genet.— 1973.— Vol.25.— P .594—597.; Riordan J.R., Rommens M., Kerem В.-S., Alon N., Rozmahel R., Grzelczak Z., Zielenski S., Lok S., Plavsic N., Chou S.-L., Drumm M.L., Iannuzzi M.C., Collins F.S., Tsui L.-C. / / Science.— 1989.— Vol.245.— P .1066—1073.; Rommens S.M., Iannuzzi C., Kerem В.-S., Drumm M.L., Melmer G., Dean M., Rozmahel R., Cole S.L., Kennedy D., Hidaka N., Zsiga M., Buchwald M., Riordan J.R., Tsui L.-C., Collins F.S. J / Ibid.— P.1059—1065.; Tsui L.-C. / / Trends Genet.— 1992.— Vol.8.— P.692—698.; Wagener D.K., Cavalli-Svorza L.L., Barakat R. / / Am. J. Hum. Genet.— 1978,— Vol.30.— P .262—270.; White R., Woodward S., Leppert M., O’Connell P., Hoff M., Herbst S., Lalouel S.-М., Dean M., Vande Woude G. / / Nature.— 1985.— Vol.318.— P .382—384.; https://journal.pulmonology.ru/pulm/article/view/3606

  10. 10
    Academic Journal

    المصدر: Medical Genetics; Том 21, № 2 (2022); 44-50 ; Медицинская генетика; Том 21, № 2 (2022); 44-50 ; 2073-7998

    وصف الملف: application/pdf

    Relation: https://www.medgen-journal.ru/jour/article/view/2045/1553; Talbi S., Bonnet C., Riahi Z., et al. Genetic heterogeneity of congenital hearing impairment in Algerians from the Ghardaïa province.International Journal of Pediatric Otorhinolaryngology. 2018;112:1-5. https://doi.org/10.1016/j.ijporl.2018.06.012; Petit C., Levilliers J., Hardelin J. Molecular genetics of hearing loss. AnnuRevGenet. 2001;35:589-646. https://doi.org/10.1146/annurev.genet.35.102401.091224; Зинченко С.П., Кириллов А.Г., Абрукова А.В., и др. Генетико-эпидемиологическое исследование наследственных (изолированных и синдромальных) нарушений слуха в Республике Чувашия. Медицинская генетика. 2007;6(5):18-28.; Петрина Н.В., Близнец Е.А., Зинченко Р.А., и др. Частота мутаций гена GJB2 у больных наследственной несиндромальной нейросенсорной тугоухостью в девяти популяциях Карачаево-Черкесской Республики. Медицинская генетика. 2017;16(2):19-25.; Шокарев Р.А., Амелина С.С., Кривенцова Н.В., и др. Генетико-эпидемиологическое и молекулярно-генетическое исследование наследственной тугоухости в Ростовской области. Медицинская генетика. 2005;4(12):556-567.; Zinchenko R.A., Sharonova E.I., Osetrova A.A. Hereditary deafness in Kirov oblast: Estimation of the incidence rate and DNA diagnosis in children.Rus J of Genetics. 2012;48(4):455-462 doi:10.1134/S1022795412030131; Zinchenko R.A., Kadyshev V.V., Еl’chinоvа G.I., et al. Study of the genetic load and diversity of hereditary diseases in the Russian population of the Karachay-Cherkess Republic.Int J Med Epidemiol Genet. 2018;9(4):34-42.; Kenneson A., Van Naarden Braun K., Boyle C. GJB2 (connexin 26) variants and nonsyndromic sensorineural hearing loss: a HuGE review. GenetMed. 2002;4:258-274. https://doi.org/10.1097/00125817-200207000-00004; Chan D. K., Chang K.W. GJB2-associated hearing loss: Systematic review of worldwide prevalence, genotype, and auditory phenotype. The Laryngoscope. 2014;124(2):E34-E53. https://doi.org/10.1002/lary.24332; Tsukada K., Nishio S., Hattori M., Usami S. Ethnic-Specific Spectrum of GJB2 and SLC26A4 Mutations: Their Origin and a Literature Review. Annals of Otology, Rhinology & Laryngology. 2015;124(5S):61S-76S; Bliznetz E.A., Galkina V.A., Matyushchenko G.N., et al. Changes in the connexin 26 gene (GJB2) in Russian patients with hearing loss: Results of long-term molecular diagnostics of hereditary nonsyndromic hearing loss.Rus J of Genetics. 2012;48(1):101-112. doi:10.1134/s1022795412010036; Животовский Л.А. Популяционная биометрия. 1991. Москва: Наука. 271с.; Lin Y.-H., Wu.P-C., Tsai C.-Y., et al. Hearing Impairment with Monoallelic GJB2 Variants. A GJB2 Cause or Non-GJB2 Cause? J Mol Diagn 2021;XX:1-13. (in Press.) https://doi.org/10.1016/j.jmoldx.2021.07.007; Resmerita I., Cozma R.S., Popescu R., et al. Genetics of Hearing Impairment in North-Eastern Romania-A Cost-Effective Improved Diagnosis and Literature Review. Genes (Basel). 2020 Dec 15;11(12):1506. doi:10.3390/genes11121506.; Bruzzone R., Veronesi V., Gomès D., et al. Loss-of-function and residual channel activity of connexin26 mutations associated with non-syndromic deafness. FEBS Lett. 2003 Jan 2;533(1-3):79-88. doi:10.1016/s0014-5793(02)03755-9.; Mani R.S., Ganapathy A., Jalvi R., et al. Functional consequences of novel connexin 26 mutations associated with hereditary hearing loss Eur J Hum Genet. 2009 Apr;17(4):502-9. doi:10.1038/ejhg.2008.179.; The National Center for Biotechnology Information. https://www.ncbi.nlm.nih.gov/clinvar/variation/17006/(accessed 31 January 2022).; Bliznetz E.A., Lalayants M.R., Markova T.G., et al. Update of the GJB2/DFNB1 mutation spectrum in Russia: a founder Ingush mutation del(GJB2-D13S175) is the most frequent among other large deletions. J Hum Genet. 2017 Aug;62(8):789-795. doi:10.1038/jhg.2017.42.; https://www.medgen-journal.ru/jour/article/view/2045

  11. 11
    Academic Journal

    المصدر: PULMONOLOGIYA; № 3 (2001); 17-20 ; Пульмонология; № 3 (2001); 17-20 ; 2541-9617 ; 0869-0189

    وصف الملف: application/pdf

    Relation: https://journal.pulmonology.ru/pulm/article/view/2817/2230; Riordan J.R., Rommens J.M., Кегет В.Sh. et al. Identification of the cystic fibrosis gene: Cloning and characterization of complementary DNA. Science 1989; 245: 1066—1073.; The Cystic Fibrosis Genetic Analysis Consortium. Population variation of common cystic fibrosis mutations. Hum. Mutat. 1994; 4: 167—177.; Verlinguer C., Kapranov N.I., Mercier B. et al. Complete screening of mutations in the coding sequence of the CFTR gene in a sample of CF patients from Russia: Identification of three novel allels. Hum. Mutat. 1995; 113: 205—209.; Morral N., Nunes V., Casals T. et al. Uniparenteral inheritance of microsatellite allerts of the cystic fibrosis gene (CFTR): identification of a 50 kilobase deletion. Hum. Mol. Genet. 1993; 2: 677—681.; Magnani C., Cremonesi L., Giunta A. et al. Short direct repeats at the breakpoints of a novel large deletion in the CFTR gene suggest a likely slipped mispairing mechanism. Hum. Genet. 1996; 98: 102—108.; Chevalier-Porst F., Bonardot A.M., Chazalette J.P. et al. 40Kilobase deletion (CF44dele4-10) removes exons 4-10 of the cystic fibrosis transmembrane conductance regulator gene. Hum. Mutat. 1998; suppl.l: 291—294.; Mickle J.E., Macek M.Jr., Fulmer-Smentek S. et al. A mutation in the cystic fibrosis transmembrane conductance regulator gene associated with elevated sweat chloride concentrations in the absence of cystic fibrosis. Hum. Mol. Genet. 1998; 7:729—735.; Lerer I., Laufer-Cahana A., Rivlin J.R. et al. A large deletion mutation in the CFTR gene (3120+1 kbdel8, 6kb): a founder mutation in the Palestinian Arabs. Hum. Mutat. 1999; 13: 337.; Dork Т., Macek M.Jr., Mekus F. et al. Characterization of a novel 21-kb deletion, CFTRdele2,3(21kb), in the CFTR gene: a cystic fibrosis mutation of Slavic origin common in Central and East Europe. Hum. Genet. 2000; 106: 259—268.; https://journal.pulmonology.ru/pulm/article/view/2817

  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
    Academic Journal
  20. 20
    Academic Journal

    المساهمون: The research was carried out within the state assignment of Ministry of Science and Higher Education of the Russian Federation., Работа выполнена в рамках государственного задания Министерства науки и высшего образования России на выполнение НИР.

    المصدر: Medical Genetics; Том 19, № 1 (2020); 24-37 ; Медицинская генетика; Том 19, № 1 (2020); 24-37 ; 2073-7998

    وصف الملف: application/pdf

    Relation: https://www.medgen-journal.ru/jour/article/view/769/474; Капранов Н.И., Каширская Н.Ю. Муковисцидоз. М.:ИД «Медпрактика-М»; 2014. 672с; Kelly J. Environmental scan of cystic fibrosis research worldwide. J Cyst Fibros. 2017;16(3):367–370. doi:10.1016/j.jcf.2016.11.002; Cfww.org [Internet]. Cystic Fibrosis Worldwide (CFW). Available from: https://www.cfww.org/. (дата обращения: 12.06.2019); MacKenzie T., Gifford A.H., Sabadosa K.A. et al. Longevity of patients with cystic fibrosis in 2000 to 2010 and beyond: survival analysis of the Cystic Fibrosis Foundation patient registry. Ann Intern Med. 2014; 161(4):233–241. doi:10.7326/M13-0636.; Шерман В.Д., Кондратьева ЕИ., Воронкова А.Ю. и др. Влияние неонатального скрининга на течение муковисцидоза на примере групп пациентов Московского региона. Медицинский совет. 2017. 18: 124–128.; Красовский С.А., Каширская Н.Ю., Амелина Е.Л. и др. Регистр больных муковисцидозом в Российской Федерации. 2012 год. Пульмонология. 2015; (Приложение): 1–58; Красовский С.А., Амелина Е.Л., Горинова Ю.В. и др. Динамика некоторых показателей здоровья взрослых больных муковисцидозом, наблюдаемых в НИИ пульмонологии, за 2003-2018 гг. Клиническая практика. 2018;9(4):26–27 doi:10.17816/clinpract9425–32; Воронкова А.Ю., Амелина Е.Л., Каширская Н.Ю. и др. Регистр больных муковисцидозом в Российской Федерации. 2017 год. М.: ИД «Медпрактика-М», 2019. 68с.; Красовский С.А., Амелина Е.Л., Черняк А.В. и др. Роль регистра московского региона в ведении больных муковисцидозом. Пульмонология. 2013;(2):27–32. https://doi.org/10.18093/08690189-2013-0-2-27-32; Красовский С.А., Черняк А.В., Амелина Е.Л. и др. Динамика выживаемости больных муковисцидозом в Москве и Московской области за периоды 1992–2001 и 2002–2011 гг. Пульмонология 2012; 3: 79–86; Quon B.S., Rowe S.M. New and emerging targeted therapies for cystic fibrosis. BMJ. 2016;352:i859. doi:10.1136/bmj.i859; https://www.ecfs.eu/ecfspr (дата обращения: 12.06.2019); Шерман В.Д., Каширская Н.Ю., Кондратьева Е.И. и др. Муковисцидоз, определение, диагностические критерии, терапия. Раздел «Диагностика муковисцидоза». Педиатрия. 2017; 96 (2): 90–99; Polgar G., Promadhat V. Pulmonary function testing in children: Techniques and standards. Philadelphia: W.B.Saunders Co; 1971; Quanjer P.H., Tammeling G.J., Cotes J.E. et al. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur.Respir. J. 1993; 6 (Suppl. 16): 5–40; Sinaasappel M., Stern M., Littlewood J. et al. Nutrition in patients with cystic fibrosis: a European Consensus. J. Cyst.Fibros. 2002; 1 (2): 51–75; Castellani C., Duff A.J.A., Bell S.C. et al ECFS best practice guidelines: the 2018 revision. J Cyst Fibros. 2018 Mar; 17(2): 153–178. doi:10.1016/j.jcf.2018.02.006; WHO. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. WHO Technical Report Series 854. Geneva: World Health Organization;1995; Петрова Н.В., Кондратьева Е.И., Красовский С.А. и др. Проект национального консенсуса «Муковисцидоз: определение, диагностические критерии, терапия». Раздел «Генетика муковисцидоза. Молекулярно-генетическая диагностика при муковисцидозе». Медицинская генетика 2016;15(11):29–45; Lee T.W.R., Brownlee L.G., Conway S.P. et al. Evaluation of a new definition for chronic Pseudomonas aeruginosa in cystic fibrosis patients. J. Cyst.Fibros. 2003; 2(1): 29–34; Proesmans M., Balinska-Miskiewicz W., Dupont L. et al. Evaluating the «Leeds criteria»for Pseudomonas aeruginosa infection in a cystic fibrosis centre. Eur.Resp. J. 2006; 27: 937–943; https://www.orkambi.com/ (дата обращения: 12.06.2019); https://www.symdeko.com/ (дата обращения: 12.06.2019); Saiman L., Marshall B.C., Mayer-Hamblett N. et al. Azithromycin in patients with cystic fibrosis chronically infected with seudomonas aeruginosa: a randomized controlled trial. JAMA. 2003; 290: 1749–1756; https://mukoviscidoz.org/doc/konsensus/CF_consensus_2017.pdf : 127–128; Krasovsky S., Gorinova Y., Amelina E. Phenotypic manifestations of rare missense mutations 41th European Cystic Fibrosis Conference, Belgrad, Serbia, 6–9 June 2018/ Journal of Cystic Fibrosis. 2018; 17(Suppl. 3): S47 EPS2.06; Marson F.A., Bertuzzo C.S., Ribeiro J.D. Classification of CFTR mutation classes. Lancet Respir Med. 2016 Aug; 4 (8):37–38 doi:10.1016/S2213-2600(16)30188-6; https://mukoviscidoz.org/doc/konsensus/CF_consensus_2017.pdf : 80-81; https://www.medgen-journal.ru/jour/article/view/769